OncLive® On Air S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
Dec 26, 2022
Hope S. Rugo, a leading expert in hormone receptor-positive breast cancer and Professor at UCSF, shares groundbreaking insights on the latest research. She discusses pivotal findings from the TROPiCS-02 trial, noting significant improvements in patient outcomes. The conversation highlights advancements in antibody-drug conjugates and their potential synergy with immunotherapy. Additionally, Rugo addresses the impact of ribociclib on post-progression treatments, emphasizing its advantages over traditional chemotherapy, and examines optimal dosing strategies from the AMELY trial.
AI Snips
Chapters
Transcript
Episode notes
Sacituzumab Govitecan Improves Outcomes In Late-Line HR+ Disease
- TROPiCS-02 showed statistically significant PFS benefit and a later OS benefit with sacituzumab govitecan in heavily pretreated HR+ HER2– patients.
- The trial also improved response rates, duration of response, and quality-of-life measures versus treatment of physician choice.
Trop-2 Expression Does Not Limit ADC Benefit
- Trope 2 expression was widespread and did not predict benefit from sacituzumab; benefit occurred across high, low, and very low H-scores.
- Therefore testing for Trop-2 expression is not required to select patients for this ADC in the studied population.
ADCs Are Rapidly Expanding Across Settings
- Antibody–drug conjugates (ADCs) are rapidly expanding across breast-cancer subtypes and moving earlier in care lines.
- Multiple ADCs and combinations with immune checkpoint inhibitors are being tested in metastatic and curative-intent settings.